Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-blind, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxy/Nal Prolonged Release Tablets Compared to Oxy PR in Subjects With Moderate to Severe, Chronic Cancer Pain

NCT01885182 is registered in ClinicalTrials.gov with Mundipharma (China) Pharmaceutical Co. Ltd as lead sponsor.

NCT NCT01885182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01885182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-blind, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxy/Nal Prolonged Release Tablets Compared to Oxy PR in Subjects With Moderate to Severe, Chronic Cancer Pain
Lead sponsor
Mundipharma (China) Pharmaceutical Co. Ltd
Phase
Phase 3
Overall status
Completed
Start date
June 1, 2013
Completion date
December 30, 2015
Enrollment
232 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, pain